




RealRate

PHARMACEUTICAL 2023

Virpax Pharmaceuticals Inc
Rank 245 of 471



The relative strengths and weaknesses of Virpax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Virpax Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 251%, being 6.4% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	19,674
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,095
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	194
Other Revenues	0
Property and Equipment	0
Research and Development	10,763
Selling, General and Administrative Expense	11,082

Output Variable	Value in 1000 USD
Assets	19,674
Liabilities	3,095
Expenses	21,845
Revenues	0
Stockholders Equity	16,579
Net Income	-21,651
Comprehensive Net Income	-21,651
BaseVar	22,404
ECR before Limited Liability	127%
Economic Capital Ratio	251%